Aug 18, 2020 12:08 AM IST
Biocon is one of the companies looking to create a vaccine to fight COVID-19
- Aug 03, 2020 12:58 PM IST
Biocon Biologics has raised $105 million so far this calendar year through two primary equity infusions.
- Jul 31, 2020 12:25 PM IST
The deal for 0.85 percent stake values Biocon Biologics at an equity valuation of Rs 26,250 crore, or $3.5 billion
- Jul 28, 2020 12:11 PM IST
Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 450 in its research report dated July 25, 2020.
- Jul 27, 2020 01:07 PM IST
A majority of the members of the task force opined that there was not enough evidence currently to get the drug included in the clinical management protocols for COVID-19, sources said.
- Jul 27, 2020 11:43 AM IST
Indian drugmakers such as Cipla, Cadila, Lupin, Dr Reddy’s, Sun Pharma and a few small-sized pharma companies such as Laurus Labs may benefit from a likely revamp of US medicare
- Jul 26, 2020 04:40 PM IST
Considering the unmet medical needs in COVID-19, Itolizumab, an already approved drug of Biocon used for treating psoriasis, was approved for "restricted emergency use" in the treatment of coronavirus by the DCGI recently.
- Jul 26, 2020 01:04 PM IST
ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 490 in its research report dated July 24, 2020.
- Jul 24, 2020 01:05 PM IST
- Jul 24, 2020 01:05 PM IST
- Jul 24, 2020 10:31 AM IST
The company's revenue from operations rose 15 percent to Rs 1,671 crore versus Rs 1,459 crore.
- Jul 21, 2020 11:30 AM IST
The licensing agreement between Malaysian subsidiary Biocon Sdn. Bhd. and Voluntis will allow Biocon Biologics to offer therapeutic product 'Insulia' to type 2 diabetes patients across several markets in the world, Biocon Biologics said in a statement.
- Jul 14, 2020 11:27 AM IST
Biocon said the approval of Itolizumab, from the DCGI, is based on the results from the successful conclusion of a randomized, controlled clinical trial at multiple hospitals in Mumbai and New Delhi.
- Jul 13, 2020 05:15 PM IST
Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications, Biocon had earlier said in a regulatory filing.
- Jul 11, 2020 05:01 PM IST
DCGI has approved to market Itolizumab (ALZUMAb) injection 25mg and 5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19, Biocon said in a release.
- Jul 02, 2020 06:25 PM IST
We expect capex (capital expenditure) spends to be $200 million in 2020-21, split equally between small molecules and the biosimilars businesses, Mittal said..
- Jun 22, 2020 10:55 AM IST
Biocon Pharma Ltd, a subsidiary of the bio-tech firm, and DKSH Business Unit Healthcare, have inked an agreement in this regard, Biocon Ltd said in a statement.
- Jun 18, 2020 06:10 PM IST
According to ICICI Direct, The pharma space has shown significant resilience in the last couple of weeks amid broader market volatility.
- Jun 12, 2020 11:04 AM IST
Biocon and Mylan N.V. announced that the US Food and Drug Administration has approved the New Drug Application for Semglee (insulin glargine injection) in vial and pre-filled pen presentations
- Jun 05, 2020 07:39 AM IST
Shaw, 67, founded Bangalore-based Biocon Limited in 1978 with just two employees and currently leads the company that is now worth close to Rs 50,000 crore by market-cap and employs more than 11,000 people.
- Jun 02, 2020 03:58 PM IST
Shaw added that the focus was needed more on flattening the death curve than the infection curve.
- Jun 01, 2020 09:48 AM IST
The PTAB also found Sanofi’s proposed amended claims for the ‘486 and ‘844 patents unpatentable.
- May 27, 2020 11:23 AM IST
Biocon Biologics has been granted licence for emergency use of CytoSorb in public interest by the Indian health regulator to treat COVID-19 patients who are 18 years of age or older.
- May 21, 2020 09:16 AM IST
- May 18, 2020 05:00 PM IST
ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 390 in its research report dated May 18, 2020.